<DOC>
	<DOCNO>NCT01886508</DOCNO>
	<brief_summary>The investigator design multicentre randomize study investigate clinical benefit nerve-spring radical hysterectomy cervical cancer . Patients FIGO stage Ia2 , Ib1 , IIa1 FIGO stage Ib2 , IIa2 neoadjuvant chemotherapy randomize either nerve-spring radical hysterectomy radical hysterectomy . The primary endpoint urodynamic outcome include maximum flow rate , residual volume , maximum vesical compliace , cystomctric capacity first desire , maximum cystomctric capacity . A total 240 patient ( 120 per treatment arm ) plan accrue study within 7 year .</brief_summary>
	<brief_title>A Multicentre Trial Nerve-Spring Radical Hysterectomy v . Radical Hysterectomy Cervical Cancer</brief_title>
	<detailed_description />
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<criteria>1 . FIGO ( 2009 ) stage Ia2 , Ib1 , IIa1 Untreated cervical cancer OR FIGO ( 2009 ) stage Ib2 IIa2 cervical cancer possible surgery neoadjuvant chemotherapy 2 . Possible radical hysterectomy nervespring radical hysterectomy 3 . Age : 17 60 year 4 . No complication operation 5 . Written inform consent 1. patient underwent radiotherapy 2 . Pathologically diagnose Pathologically diagnose squamous carcinoma , Small Cell Carcinoma , Small Cell Carcinoma 3 . Patients uncontrolled diabetes uncontrolled hypertension 4. patient neurogenic bladder dysfunction 5. patient uterine prolapse 6 . Patients psychiatric illness 7 . Patients active infection 8 . Patients heart failure , unstable angina , myocardial infarction within past 6 month 9 . Patients unable undergo radical hysterectomy complication excessive obesity , liver cirrhosis , bleeding tendency</criteria>
	<gender>Female</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>